R. Cohen

Vaccinoscopie® : étude de l’évolution annuelle entre 2008 et 2011 de la couverture vaccinale des enfants de moins de 7 ans dans la population française

UNLABELLED Assessing vaccination coverage (VC) is a critical part of adherence to immunization guidelines and beyond vaccine effectiveness can fill possible gaps and optimize VC. The aim of this study was to measure annual VC trends (2008-2011) among children 0-6years of age. METHODS An Internet survey was conducted using a self-administrated questionnaire to a representative sample (quota method) of mothers reporting their childs immunization record. RESULTS Diphtheria-tetanus-poliomyelitis-pertussis VC (complete schedule) was 96.0% at 6 years of age in 2010. Hepatitis B VC (≥1 dose) in the 6- to 11-month-old population increased from 54.6% in 2008 to 80.5% in 2011, but only 34.7% of 6-year-old had received a complete schedule in 2010. Pneumococcal conjugate vaccine VC (complete schedule) increased to 92.7% in the 24- to 35-month-old population. Measles-mumps-rubella (MMR) VC (2 injections) increased in 24- to 35-month-olds from 60.3% in 2008 to 81.0% in 2011. In 2011, 64.2% of 24- to 35-month-olds had received a second dose of MMR vaccine before 25 months vs. 45.4% in 2008. BCG VC in 12- to 35-month-olds was 73.2% in Île-de-France, where vaccination is recommended in all children vs. 15.5% elsewhere (vaccination only recommended in high-risk children). CONCLUSION This study shows a significant improvement of VC in young French children. However, outreach efforts should continue to be made, especially to adolescent and adult populations, in whom VC is very low.

Mémoire originalVaccinoscopie® : étude de l’évolution annuelle entre 2008 et 2011 de la couverture vaccinale des enfants de moins de 7 ans dans la population françaiseAnnual trends (2008–2011) in early childhood vaccination coverage for the French population: The Vaccinoscopie® study

UNLABELLED Assessing vaccination coverage (VC) is a critical part of adherence to immunization guidelines and beyond vaccine effectiveness can fill possible gaps and optimize VC. The aim of this study was to measure annual VC trends (2008-2011) among children 0-6years of age. METHODS An Internet survey was conducted using a self-administrated questionnaire to a representative sample (quota method) of mothers reporting their childs immunization record. RESULTS Diphtheria-tetanus-poliomyelitis-pertussis VC (complete schedule) was 96.0% at 6 years of age in 2010. Hepatitis B VC (≥1 dose) in the 6- to 11-month-old population increased from 54.6% in 2008 to 80.5% in 2011, but only 34.7% of 6-year-old had received a complete schedule in 2010. Pneumococcal conjugate vaccine VC (complete schedule) increased to 92.7% in the 24- to 35-month-old population. Measles-mumps-rubella (MMR) VC (2 injections) increased in 24- to 35-month-olds from 60.3% in 2008 to 81.0% in 2011. In 2011, 64.2% of 24- to 35-month-olds had received a second dose of MMR vaccine before 25 months vs. 45.4% in 2008. BCG VC in 12- to 35-month-olds was 73.2% in Île-de-France, where vaccination is recommended in all children vs. 15.5% elsewhere (vaccination only recommended in high-risk children). CONCLUSION This study shows a significant improvement of VC in young French children. However, outreach efforts should continue to be made, especially to adolescent and adult populations, in whom VC is very low.

Evolution of hepatitis B vaccine coverage rates in France between 2008 and 2011.

UNLABELLED High vaccine coverage rates were reached for hepatitis B vaccination in teenagers nearly two decades ago (1995), but controversy sharply decreased the rate of vaccination in France, requiring high remobilization in its favor and careful monitoring of vaccine coverage rates. We report the results of Vaccinoscopie(®) survey which has monitored the yearly evolution of vaccine coverage rates since 2008. METHOD A representative national sample of 5250 mothers was recruited in 2011: 3000 mothers of infants (1000 for each of the following age range: 0-11 months, 12-23 months, and 24-35 months of age) and 2250 mothers of teenagers. They all answered a self-administered questionnaire on the Internet and reported all vaccinations included in their childs health record. RESULTS In 2011, 82.4% (CI 95%: 77.6-87.1) of infants 6-8 months of age were given hepatitis B vaccination before six months of age and 71.9% (CI 95%: 66.3-77.5) of children 24-26 months of age were fully immunized before 24 months of age. France should reach its objectives for infants thanks to the hexavalent vaccine, but this is not the case for teenagers since in 2011, at 14-16 years of age, only 55.4% (CI 95%: 53.3-57.4) had started their vaccination schedule and 37.4% (CI 95%: 35.4-39.4) were fully vaccinated. CONCLUSION This recent data, specially concerning teenagers, should lead to corrective measures rapidly to reach vaccine coverage targets for this vaccination.

Papillomavirus vaccination in France according to 2008 to 2012 Vaccinoscopie(®) data.

UNLABELLED Vaccination against human papillomavirus infections (HPV), introduced in the French vaccinal schedule in 2007, was recommended until the end of 2012 for 14-year-old girls, with a catch-up policy until 23years of age. We followed the evolution of this vaccine coverage rate (VC) during these 5years in the Vaccinoscopie(®) survey. METHOD We present the analysis of data collected in 2012 from a sample of 1136 mothers of girls 14 to 16years of age. They answered a self-administered questionnaire on Internet and reported all vaccinations mentioned in their daughters health record. RESULTS In 2012, respectively 12.9%, 33.6%, and 48.1% of girls 14, 15 and 16years of age had begun HPV vaccination (≥1 dose received) and respectively 4.3%, 23.6%, and 40.5% of them had received a complete vaccination schedule (3 doses), i.e. 31.7% of 14-16-year-old girls had started the vaccination schedule and 22.9% were fully vaccinated. VC for ≥1 dose had decreased between 2009 and 2012 (-14 points in 14-year-old girls, -16 points in 15-year-old girls, and -11 points between 2009 and 2012 in 16-year-old girls). Regional VCs were heterogeneous. CONCLUSION HPV VC is clearly insufficient. It is essential that physicians concerned by HPV vaccination be mobilized and take every opportunity to inform, reassure, and vaccinate teenage girls. HPV vaccination has been recommended for girls between 11 and 14years of age since 2013, which could help improve adherence to vaccination.